• Return to Headlines

Endocyte Inc has the Highest Price to Forward Sales in the Pharmaceuticals Industry (ECYT, RVNC, MDCO, ZGNX, ITCI)

By Amy Schwartz

Below are the three companies in the Pharmaceuticals industry with the highest price to forward sales ratios. The ratio shows how much Wall Street values every dollar of the company's future sales and is useful in comparing comparable companies. Generally the lower the ratio, the more attractive the investment.

Endocyte Inc ranks highest with a a price to forward sales ratio of 40,194.33. Following is Revance Therapeu with a a price to forward sales ratio of 213.67. Medicines Comp ranks third highest with a a price to forward sales ratio of 201.37.

Zogenix Inc follows with a a price to forward sales ratio of 37.21, and Intra-Cellular T rounds out the top five with a a price to forward sales ratio of 15.80.

SmarTrend recommended that subscribers consider buying shares of Zogenix Inc on November 14th, 2019 as our technology indicated a new Uptrend was in progress when shares hit $45.40. Since that recommendation, shares of Zogenix Inc have risen 4.6%. We continue to monitor Zogenix Inc for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.

Keywords: highest price to forward sales endocyte inc revance therapeu medicines comp zogenix inc intra-cellular t

Ticker(s): ECYT RVNC MDCO ZGNX ITCI